Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study

[1]  P. Galle,et al.  Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[3]  M. A. Khan,et al.  Clinical epidemiology and disease burden of nonalcoholic fatty liver disease , 2017, World journal of gastroenterology.

[4]  F. T. E. Group,et al.  Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study , 2017, Diabetologia.

[5]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[6]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[7]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[8]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[9]  Q. Anstee,et al.  Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.

[10]  L. Henry,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. , 2016, Clinics in liver disease.

[11]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[12]  L. Henry,et al.  Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease , 2015, PharmacoEconomics.

[13]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[14]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[16]  C. Jo,et al.  Cost-of-illness studies: concepts, scopes, and methods , 2014, Clinical and molecular hepatology.

[17]  M. Rau,et al.  Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. , 2014, Deutsches Arzteblatt international.

[18]  S. Nusrat,et al.  Cirrhosis and its complications: evidence based treatment. , 2014, World journal of gastroenterology.

[19]  Donghee Kim,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease , 2014 .

[20]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging , 2013, Frontline Gastroenterology.

[21]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[22]  S. Alavian,et al.  Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation , 2013, Hepatitis monthly.

[23]  A. McCullough,et al.  Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. , 2012, Gastroenterology & hepatology.

[24]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[25]  A. Sanyal.  NASH: A global health problem , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[27]  G. Bedogni,et al.  Epidemiology of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[28]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[29]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[30]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[31]  P. Thampanitchawong,et al.  Liver biopsy:complications and risk factors. , 1999, World journal of gastroenterology.

[32]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[33]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .